Changing the paradigms of treatment in peripheral T-cell lymphoma:from biology to clinical practice
| Autor: | Susan E. Bates, Govind Bhagat, Martin Bjerregaard Pedersen, Karthik A. Ganapathi, Dejan Radeski, Owen A. O'Connor, Francesco d'Amore |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Disease CHOP Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Genetic Predisposition to Disease Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Lymphoma T-Cell Peripheral Cancer medicine.disease Peripheral T-cell lymphoma Lymphoma Clinical Practice Leukemia Cell Transformation Neoplastic Immunology Neoplasm Recurrence Local business |
| Zdroj: | O'Connor, O A, Bhagat, G, Ganapathi, K, Pedersen, M B, D'Amore, F, Radeski, D & Bates, S E 2014, ' Changing the paradigms of treatment in peripheral T-cell lymphoma : from biology to clinical practice ', Clinical Cancer Research, vol. 20, no. 20, e006363, pp. 5240-54 . https://doi.org/10.1158/1078-0432.CCR-14-2020 |
| DOI: | 10.1158/1078-0432.CCR-14-2020 |
| Popis: | Despite enormous advances in our understanding of aggressive lymphomas, it is clear that progress in the peripheral T-cell lymphomas (PTCL) has lagged well behind other B-cell malignancies. Although there are many reasons for this, the one commonly cited notes that the paradigms for diffuse large B-cell lymphoma (DLBCL) were merely applied to all patients with PTCL, the classic “one-size-fits-all” approach. Despite these challenges, progress is being made. Recently, the FDA has approved four drugs for patients with relapsed/refractory PTCL over the past 5 years, and if one counts the recent Japanese approval of the anti-CCR4 monoclonal antibody for patients with adult T-cell leukemia/lymphoma, five drugs have been approved worldwide. These efforts have led to the initiation of no fewer than four randomized clinical studies exploring the integration of these new agents into standard CHOP (cyclophosphamide–Adriamycin–vincristine–prednisone)–based chemotherapy regimens for patients with newly diagnosed PTCL. In addition, a new wave of studies are exploring the merits of novel drug combinations in the disease, an effort to build on the obvious single-agent successes. What has emerged most recently is the recognition that the PTCL may be a disease-characterized by epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors, and open the door for even more creative combination approaches. Nonetheless, advances made over a relatively short period of time are changing how we now view these diseases and, hopefully, have poised us to finally improve its prognosis. See all articles in this CCR Focus section, “Paradigm Shifts in Lymphoma.” Clin Cancer Res; 20(20); 5240–54. ©2014 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|